Development · 1 Oct 2026
5 publishers have reported this development. Each act of reporting is below, cited.
The US will exempt select Indian specialty drugs and their ingredients from a new 100% pharma tariff.
The United States Commerce Department has issued a notice clearing a complete tariff waiver on certain specialty pharmaceutical drugs and their associated ingredients from India and 19 partner nations.
The US Department of Commerce named India among 20 jurisdictions eligible for an exemption from the country’s new Section 232 pharmaceutical tariffs, granting Indian exporters of select specialty medicines zero US tariffs.
The US will not charge any tariff on certain speciality drugs and associated ingredients used for the treatment of rare medical conditions imported from India and 19 other countries.
The US government has exempted a set of patented speciality pharmaceutical products and ingredients imported from India and 19 other countries from duties.
The US exempted select specialty pharmaceutical products and associated ingredients imported from India and 19 other countries from a 100% tariff.
The US will not charge any ad valorem tariff on certain drugs and associated ingredients used to treat rare medical conditions when they are imported from India and 19 other jurisdictions.
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.